Table 1.
Baseline Characteristics of Patients Who Met AS Criteria and Underwent RARP
| Characteristic | Total (n = 217) | NLR <2.6 (n = 110) | NLR ≥2.6 (n = 107) | P Value |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age (years) | .225 | |||
| Median | 59 | 58 | 60 | |
| IQR | 55–63 | 54–63 | 55–63 | |
| Race (n) | .012 | |||
| White | 183 (84.3) | 85 (77.3) | 98 (91.6) | |
| African American | 26 (12) | 20 (18.2) | 6 (5.6) | |
| Other | 8 (3.7) | 5 (4.5) | 3 (2.8) | |
| BMI (kg/m2) | .062 | |||
| Median | 27.3 | 27.5 | 27.1 | |
| IQR | 25.2–30.1 | 26.1–30.5 | 25.0–29.4 | |
| Preoperative PSA (ng/mL) | .935 | |||
| Median | 4.4 | 4.4 | 4.4 | |
| IQR | 3.6–5.9 | 3.7–5.7 | 3.6–6.2 | |
| Positive core (n) | .815 | |||
| 1 | 110 (50.7) | 54 (49.1) | 56 (52.3) | |
| 2 | 67 (30.9) | 34 (30.9) | 33 (30.8) | |
| 3 | 40 (18.4) | 22 (20.0) | 18 (16.8) | |
| Maximum cancer in core (%) | .630 | |||
| Mean | 17.1 | 16.7 | 17.6 | |
| Range | 1–50 | 1–50 | 1–50 | |
| Preoperative Gleason score | – | |||
| Median | 6 | 6 | 6 | |
| IQR | 6–6 | 6–6 | 6–6 | |
| Preoperative Hb (g/dL) | .275 | |||
| Median | 14.9 | 14.7 | 15.1 | |
| IQR | 14.2–15.6 | 14.2–15.3 | 14.1–15.7 | |
| WBC count (×109/L) | <.0001 | |||
| Median | 6.4 | 5.7 | 7.0 | |
| IQR | 5.4–7.6 | 4.9–6.8 | 6.2–8.0 | |
| Neutrophil (×109/L) | <.0001 | |||
| Median | 4.0 | 3.3 | 4.8 | |
| IQR | 3.2–5.0 | 2.6–3.9 | 4.1–5.7 | |
| Lymphocyte (×109/L) | <.0001 | |||
| Median | 1.52 | 1.8 | 1.3 | |
| IQR | 1.25–1.88 | 1.5–2.2 | 1.1–1.5 | |
| Neutrophil (%) | <.0001 | |||
| Median | 63.0 | 57.7 | 69.3 | |
| IQR | 57.5–69.23 | 52.3–60.7 | 67.1–72.8 | |
| Lymphocyte (%) | <.0001 | |||
| Median | 24.9 | 30.7 | 20.1 | |
| IQR | 20.2–30.8 | 27.6–34.8 | 17.2–22.3 | |
| Clinical stage (n) | .174 | |||
| T1 | 205 (94.5) | 106 (96.4) | 99 (92.5) | |
| T2a | 12 (5.5) | 4 (3.6) | 8 (7.5) | |
| Medication and medical history (n) | ||||
| Aspirin | .664 | |||
| No | 149 (68.7) | 74 (67.3) | 75 (70.1) | |
| Yes | 68 (31.3) | 36 (32.7) | 32 (29.9) | |
| Statin | 1.00 | |||
| No | 138 (63.6) | 70 (63.6) | 68 (63.6) | |
| Yes | 79 (36.4) | 40 (36.4) | 39 (36.4) | |
| Steroid | .618 | |||
| No | 214 (98.6) | 109 (99.1) | 105 (98.1) | |
| Yes | 3 (1.4) | 1 (0.9) | 2 (1.9) | |
| Diabetes | .028 | |||
| No | 203 (93.5) | 107 (97.3) | 96 (89.7) | |
| Yes | 14 (6.5) | 3 (2.7) | 11 (10.3) | |
| Hematologic malignancy | .984 | |||
| No | 215 (99.1) | 109 (99.1) | 106 (99.1) | |
| Yes | 2 (0.9) | 1 (0.9) | 1 (0.9) | |
| Pathologic characteristics | ||||
| Pathologic stage | .573 | |||
| T2 | 199 (91.7) | 101 (91.8) | 98 (91.6) | |
| T3a | 18 (8.3) | 9 (8.2) | 9 (8.4) | |
| Pathologic Gleason score | .019 | |||
| 6 | 159 (73.3) | 79 (71.8) | 80 (74.8) | |
| 7 | 52 (24.0) | 31 (28.2) | 21 (19.6) | |
| ≥8 | 6 (2.8) | 0 (0) | 6 (5.6) | |
| Upstaging (≥T3a) | .573 | |||
| No | 199 (91.7) | 101 (91.8) | 98 (91.6) | |
| Yes | 18 (8.3) | 9 (8.2) | 9 (8.4) | |
| Upgrading (PGS ≥7) | .368 | |||
| No | 159 (73.3) | 79 (71.8) | 80 (74.8) | |
| Yes | 58 (26.7) | 31 (28.2) | 27 (25.2) | |
| Prostate weight (g) | .420 | |||
| Median | 49.0 | 49.0 | 48.0 | |
| IQR | 40.0–58.5 | 40.0–61.3 | 39.0–58.0 | |
| Margin status | .549 | |||
| Negative | 189 (87.1) | 96 (87.3) | 93 (86.9) | |
| Positive | 28 (12.9) | 14 (12.7) | 14 (13.1) | |
| Biochemical recurrence | 6 (2.8) | 4 (3.6) | 2 (1.9) | .355 |
Data presented as n (%), unless otherwise noted.
Abbreviations: AS = active surveillance; BMI = body mass index; Hb = hemoglobin; IQR = interquartile range; NLR = neutrophil-to-lymphocyte ratio; PGS = pathologic Gleason score; PSA = preoperative prostate-specific antigen; RARP = robot-assisted radical prostatectomy; WBC = white blood cell.